Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 30;10(12):1925.
doi: 10.3390/antiox10121925.

Radioresistance in Prostate Cancer: Focus on the Interplay between NF-κB and SOD

Sameera Kumar  1 , Daret St Clair  2
Affiliations
Review

Radioresistance in Prostate Cancer: Focus on the Interplay between NF-κB and SOD

Sameera Kumar et al. Antioxidants (Basel). .

Abstract

Prostate cancer occurs frequently in men and can often lead to death. Many cancers, including prostate cancer, can be initiated by oxidative insult caused by free radicals and reactive oxygen species. The superoxide dismutase family removes the oxygen-derived reactive oxygen species, and increased superoxide dismutase activity can often be protective against prostate cancer. Prostate cancer can be treated in a variety of ways, including surgery, androgen deprivation therapy, radiation therapy, and chemotherapy. The clinical trajectory of prostate cancer varies from patient to patient, but more aggressive tumors often tend to be radioresistant. This is often due to the free-radical and reactive-oxygen-species-neutralizing effects of the superoxide dismutase family. Superoxide dismutase 2, which is especially important in this regard, can be induced by the NF-κB pathway, which is an important mechanism in radioresistance. This information has enabled the development of interventions that manipulate the NF-κB mechanism to treat prostate cancer.

Keywords: NF-κB; prostate cancer; radiation; superoxide dismutase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Higano C.S., Crawford E.D. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol. Oncol. 2011;29:S1–S8. doi: 10.1016/j.urolonc.2011.08.013. - DOI - PubMed
    1. Nakazawa M., Paller C., Kyprianou N. Mechanisms of Therapeutic Resistance in Prostate Cancer. Curr. Oncol. Rep. 2017;19:13. doi: 10.1007/s11912-017-0568-7. - DOI - PMC - PubMed
    1. James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Ritchie A.W.S., Amos C.L., Gilson C., Jones R.J., et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N. Engl. J. Med. 2017;377:338–351. doi: 10.1056/NEJMoa1702900. - DOI - PMC - PubMed
    1. Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y., Özgüroğlu M., Ye D., Feyerabend S., Protheroe A., et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700. doi: 10.1016/S1470-2045(19)30082-8. - DOI - PubMed

LinkOut - more resources